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Background/aim: High mobility group box- 1 (HMGB- 1) is a nuclear protein acting as a proinflammatory molecule. The serum
HMGB- 1 levels were found elevated in chronic inflammatory diseases. In this cross-sectional study, serum HMGB- 1 levels in Behcet’s
disease (BD) patients and healthy controls (HC) were studied. Also, its association with disease activity scores and clinical findings were
evaluated.
Materials and methods: Ninety BD patients and 50 age-sex matched HC were included in the study. Disease activity scores were
assessed by Behcet Disease Current Activity Form (BDCAF) and Behcet Syndrome Activity Score (BSAS). Serum HMGB- 1 levels were
measured using a commercial ELISA kit. A p value of < 0.05 was considered to be statistically significant.
Results: Serum HMGB- 1 levels were significantly higher in BD than in HC (43.26 pg/mL and 16.73 pg/mL; p < 0.001, respectively).
Serum HMGB- 1 levels were statistically significantly associated with presence of erythema nodosum (EN) and genital ulcers in the last
one month prior to recruitment (p = 0.041 and p < 0.001, respectively). BDCAF and BSAS scores were positively correlated with serum
HMGB- 1 level ( p = 0.03 and p = 0.02, respectively).
Conclusion: HMGB - 1 may play a role in the development of BD. Also, due to its positive correlation with disease activity indices, it
can be used as a novel disease activity parameter in BD.
Key words: High mobility group box- 1, autoimmune diseases, Behcet’s disease, inflammation

1. Introduction
Behcet’s disease is a chronic inflammatory disease
characterized by various systemic symptoms including
skin lesions such as recurrent oral ulcers, genital
ulcers, EN and papulopustular eruption (PPE), eye
involvement such as uveitis and retinal vasculitis,
musculoskeletal manifestations such as arthritis and
arthralgia, and gastrointestinal, neurological, vascular,
cardiac and pulmonary involvements [1]. Although its
etiopathogenesis is not fully known, genetic factors and
immune dysregulation are considered to play a significant
role in the development of this disease [2].
High mobility group box- 1 (HMGB- 1) is a
nonhistone protein with important biological activities
both inside and outside the cell. HMGB- 1 is comprised of
215 amino acids, has a molecular weight of ~ 25 kDa, and
includes two DNA-binding domains (A and B boxes) and

a C-terminal acidic tail [3]. HMGB- 1 binds to different
molecules through different receptors, leading to different
metabolic functions. Receptor for Advance Glycation End
Product (RAGE), a transmembrane protein belonging
to the immunoglobulin (Ig) superfamily, is the first
receptor described for HMGB- 1 [4]. Binding of HMGB1 with RAGE causes cell migration [5], whereas binding
with Toll-like receptor 4 (TLR4) mediates inflammation
through NF-κB activation and production of cytokines
such as interleukin- 6 (IL- 6) and tumor necrosis factor-α
(TNF-α) by macrophages [6-8], and binding to p53
causes gene transcription [9]. Extracellular HMGB- 1
arouses a potent inflammatory response stimulating the
release of proinflammatory cytokines in neutrophils and
macrophages [10]. Elevated serum HMGB- 1 level is
reported in many autoimmune and inflammatory diseases
[11–13].
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Neutrophilic infiltration, endothelial cell swelling,
necrosis and elevated serum levels of cytokines that prime
the neutrophils were shown in the pathogenesis of BD [14].
These findings suggested BD to be a neutrophilic vasculitis
[15]. Activated neutrophils in BD secrete cytokines
that both prime themselves and stimulate T-helper- 1
cells [14]. Emmi G and his collegeues demonstrated
the important role of neutrophils in the development
of thrombotic events in BD. They showed an increased
leucocyte oxidative stress and radical oxygen species
leading to posttranslational carbonylation of fibrinogen
and reduced plasmin lysis, which were thought to play role
in thrombus formation in BD [16]. On the other hand,
intensive leucocytes recruitment is the most significant
feature of HMGB- 1 associated inflammation [17].
HMGB- 1 can directly activate neutrophils to produce IL1β, IL- 8 and TNF-α, which are one of the main cytokines
of inflammation and related diseases [18]. With respect to
this knowledge, we aimed to evaluate the role of HMGB- 1
in BD and its association with clinical manifestations and
disease activity.
2. Materials and methods
2.1. Study population
Ninety BD patients over the age of 18 who were diagnosed
according to the 1990 International Study Group criteria
for Behcet’s Disease [19] and followed between March 2018
and March 2019 at Ankara University Faculty of Medicine,
Ibn-i Sina Hospital, Behcet’s Disease Multidisciplinary
Diagnosis and Treatment Unit, and 50 age and sex
compatible HC were recruited consequtively for the study.
Patients with autoimmune or autoinflammatory diseases
other than BD and patients with other comorbidities or
infectious diseases during recruitment were excluded
from the study.
2.2. Study design
Demographic data, clinical and treatment features of
BD patients were obtained from patients at the time of
study recruitment and also from the hospital records.
Mucocutaneous manifestations included recurrent
aphthous stomatitis, genital ulcers, EN, PPE and skin
pathergy reaction. Papulopustular eruptions were defined
as folliculitis or acne like lesions with sterile erythematous
papules or pustules that are localized mostly on the lower
extremities but also on upper extremities, trunk, face and
neck [20, 21]. Mucocutanous involvement was assessed
by physical examination at the time of recruitment. Joint
involvement was described as synovial inflammation which
could not be otherwise explained by any other inflammatory
arthritis and was diagnosed by physical examination and
imaging studies as conventional radiography, ultrasound
and/or magnetic resonance imaging (MRI). Ocular
involvement included inflammation of uvea and retina

(namely, uveitis and retinis, respectively). Uveitis was
classified as isolated anterior uveitis, posterior uveitis and
panuveitis according to ophthalmologist’s examination.
Vascular involvement included both arterial and venous
involvements. Pulmonary and/or peripheral artery
aneurisms and/or thrombosis were classified as arterial
involvement; whereas deep venous thromboses were
classified as venous involvement. The diagnosis of vascular
involvement was confirmed by arterial and/or venous
doppler ultrasonography, computed tomography, MRI,
echocardiography and/or scintigraphy. Gastrointestinal
system (GIS) involvement was defined as presence of
punched-out or aphthous ulcers in endoscopic studies
in patients with gastrointestinal symptoms that could
not be explained by other diseases. Central nervous
system (CNS) involvement was defined as presence
of parenchymal disease and/or cerebral venous sinus
thrombosis in neuroimaging studies in patients with
neurological symptoms that could not be explained by
another systemic/neurological disease or usage of any
drug. Major organ involvement (MOI) was defined as the
presence of at least one of the eye, vascular, CNS or GIS
involvements as described previously.
The disease activity of BD was evaluated at hospital
visit during recruitment. In order to evaluate disease
activity; two measures were used. One of the measures
used was Behcet Syndrome Activity Score (BSAS) which
is a ten-question patient derived assessment tool. It scores
the degree of discomfort caused by the current clinical
findings over the last four weeks of patient assessment
by the patient visual analogue scales [22, 23]. It is scored
between 0 - 100. The other activity index used was Behcet
Disease Current Activity Form (BDCAF) which is a
commonly used index that scores the absence or presence
of clinical manifestations over the last four weeks prior to
patient hospital visit [23, 24]. The total score is 12. Patients
with a score of ≥ 2 were accepted as “active” [24, 25]. Both
indices had been translated to Turkish correctly and are
commonly used in daily practice [23].
Peripheral blood samples were drawn from BD patients
for routine evaluation of Erythrocyte Sedimentation Rate
(ESR) (0 - 20 mm/h), C-Reactive protein (CRP) (0 - 5
mg/L) and complete blood count (CBC).
2.3. Enzyme-linked immunosorbent assay (ELISA)
Peripheral venous blood samples were collected from
BD patients and HC by using proper tubes to determine
their serum HMGB- 1 levels, and then the samples were
centrifuged at 3000 rpm for 15 minutes and stored at - 80
°C. The samples were processed using ELISA kits (LifeSpan
BioSciences, Inc., Seattle, USA) (Catalog No: LS-F11641)
at Ankara University, Faculty of Medicine, Ibn-i Sina
Hospital Microbiology Laboratory.
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2.4. Ethical considerations
The study was conducted according to the Declaration of
Helsinki and written consent was received from patients.
The study protocol was approved by Ankara University
Faculty of Medicine Ethics Board (Approval Number: 12
- 724 - 17).
2.5 Statistical analysis
Data were statistically analyzed using the IBM SPSS
for Windows Version 22.0 (SPSS, Chicago, USA). The
normality of numerical variables was examined with
the Kolmogorov Smirnov test. If numerical variables
had normal distribution, they were shown by mean ±
standard deviation (SD), otherwise by median (minimum
and maximum) values. Categorical variables were shown
using numbers and percentages. The comparison between
healthy control and BD patients’ demographic data
was examined using the t test when the variables were
normally distributed and using the Mann–Whitney U test
when they were not normally distributed. The relationship
of BD patients’ clinical findings with HMGB- 1 levels
was examined using the Mann–Whitney U test. Power
analyses were performed using G*Power version 3.0.10 for
sample size calculation. Statistically significance level was
considered as p < 0.05.
2.6 Funding
The study was funded by the Scientific Research Projects
Unit of Ankara University (Project number: 18L0230003).
3. Results
3.1. Demographic and clinical features
The demographic and clinical features of BD patients were
summarized in Table 1. Median serum HMGB- 1 levels
were significantly higher in BD patients (43.26 (0 – 221.33)
pg/mL) in comparison to HC (16.73 (0– 41.95) pg/mL) (p
< 0.001).
In four patients, colchicine was ceased due to side
effects. Azatioprin was the mostly commonly used
(22.22%) disease modifying antirheumatic drug. In one
patient, cyclophosphamide was used due to the acute
thrombosis of superior vena-cava. Adalimumab was the
only preferred biological disease-modifying antirheumatic
drug in our patients, which was used for recurrent
panuveitis and refractory gastrointestinal involvement.
3.2. Association of serum HMGB- 1 level with BD
manifestations
We observed that in patients who had genital ulcers and
EN-like lesions in the past four weeks prior to recruitment
had significantly higher levels of HMGB- 1. (p = 0.041 and
p < 0.001) (Table 2).
No statistically significant difference was found
between patients with and without vascular, ocular or
MOI involvements (p = 0.552, p = 0.329 and p = 0.212,
respectively) (Table 3).
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3.3. Association of serum HMGB- 1 level with disease
activity scores
There was weak but positive correlation between serum
HMGB- 1 levels, BSAS and BDCAF scores (r = 0.24, p =
0.022 and r = 0.24, p = 0.026, respectively). Serum HMGB1 level of active BD patients (n = 52) was significantly
higher than inactive patients (n = 38) (median 45.17 and
27.97 pg/mL respectively; p = 0.035).
4. Discussion
HMGB- 1 is a nonhistone protein that can be found both
inside and outside the cell and has different functions by
its location [26]. It regulates transcription and autophagy
when it is bound with DNA within the cell [26]. During
cell activation, death or damage; it is released outside of the
cell, acting as an alarmin or Damage Associated Molecular
Pattern (DAMP) to activate the innate immune system
[27]. Due to its interaction with chemokines, cytokines
and Pathogen Associated Molecular Pattern (PAMP),
HMGB- 1 is considered to play a role in the pathogenesis
of inflammatory and autoimmune diseases [28].
In the literature, there are studies showing that serum
HMGB- 1 levels are higher in patients with chronic
systemic inflammatory diseases when compared to
HC [12, 29–31]. Taniguchi et al. [32] measured the
HMGB- 1 concentrations in sera and synovial fluids of 30
rheumatoid arthritis (RA) and 30 osteoarthritis patients
and found statistically significant higher concentrations of
HMGB- 1 in both sera and synovial fluids of RA patients.
Goldstein et al. [29] also showed that serum HMGB- 1
levels were higher in RA patients compared to HC and
that it correlated significantly with disease activity score
of 28 joints. In the study with 147 ankylosing spondylitis
(AS) patients, serum HMGB- 1 level of AS patients was
significantly higher than in HC and it was correlated
positively with AS disease activity indices such as Bath
Ankylosing Spondylitis Disease activity index (BASDAI),
Bath Ankylosing spondylitis Functional index (BASFI),
Ankylosing spondylitis disease activity score-ESR
(ASDAS-ESR), ASDAS-CRP, ESR, and CRP [31]. A study
conducted with 169 Granulomatosis with polyangiitis
(GPA) patients in Germany [33] demonstrated higher
serum HMGB- 1 levels in GPA in comparison to HC and
also in this study, higher serum HMGB- 1 levels were
found in patients with more dominant granulomatous
manifestations. To the best of our knowledge, there are
only two studies in the literature evaluating the serum
HMGB- 1 levels in BD patients.
In our study, serum HMGB- 1 level was found to be
significantly higher in BD patients than in HC. The results of
the other two studies evaluating the serum HMGB- 1 levels
in BD patients support our results [24,34]. Hyperfunction
of neutrophils, vascular injury and autoimmune responses
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Table 1. Demographic, clinical characteristics since disease onset and laboratory findings of BD patients.
Behcet’s disease

Healthy control

p value

Age, years, mean (± SD)

42.16 ± 9.69

39.00 ± 10.65

0.128

Sex, women, n (%)

51 (56.70)

32 (64.00)

0.401

Disease duration (years), median (min - max)

10 (1–37)

16.73 (0– 41.95)

< 0.001*

Clinical manifestations, n (%)
Oral ulcers

90 (100.00)

Genital ulcers

68 (75.55)

Erythema nodosum like lesions

52 (57.77)

Papulopustuler eruption

59 (65.55)

Pathergy positivity

37 (41.11)

Uveitis

27 (30.00)

Retinal vasculitis

2 (2.22)

CNS involvement

7 (7.77)

GIS involvement

2 (2.22)

Arthralgia

75 (83.33)

Arthritis

15 (16.66)

Arterial involvement

3 (3.33)

Venous involvement

25 (27.77)

Major organ involvement

47 (52.22)

Treatment, n (%)
Colchicine

86 (95.55)

Azathioprine

20 (22.22)

Mycophenolate mofetil

1 (1.11)

Methotrexate

1 (1.11)

Cyclophosphamide

1 (1.11)

Sulfasalazine

2 (2.22)

Adalimumab

2 (2.22)

Laboratory findings, median (min - max)
Serum HMGB- 1 level (pg/mL)

43.26 (0 –221.33)

ESR (mm/h)

9 (1– 48)

CRP (mg/L)

2.25 (0.30–169.00)

MPV (fL)

10.50 (8.30– 12.50)

Neutrophil/lymphocyte ratio

1.90 (0.67– 6.56)

Platelet/lymphocyte ratio

122.05(50.7–373.8)

Activity Scores, median (min - max)
BSAS

10 (0–54)

BDCAF

2 (0–6)

T test was used for parametric data.
Mann–Whitney U test was used for nonparametric data.

are involved in the pathogenesis of BD [14]. Innate immune
system plays a critical role in the initiation and aggregation
of inflammation in BD [34]. It was demonstrated that
polymorphonuclear neutrophils adhere to endothelial

cells and migrate to inflamed areas, which showed the
central role of leucocytes in the pathogenesis of BD. In
BD, there is not only enhanced neutrophil chemotaxis,
but also the neutrophils are overreactive, which was
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Table 2. Comparison of serum HMGB- 1 levels in BD patients with and without
clinical involvement in the last four weeks.
Current clinical findings
(n)

HMGB- 1 level
median (min - max)

p value

(+) (n = 60)

44.03 (0–221.33)

0.218

(-) (n = 30)

39.11 (0–103.91)

Oral ulcer

Genital ulcer
(+) (n = 7)

47.11 (43.26–221.33)

(-) (n = 83)

42.50 (0–103.91)

0.041*

EN-like lesion
(+) (n = 14)

51.83 (27.90–75.25)

(-) (n = 76)

39.85 (0–221.33)

< 0.001*

Papulopustular eruption
(+) (n = 26)

45.17 (5.46–62.42)

(-) (n = 64)

41.36 (0–221.33)

0.216

Arthralgia/arthritis
(+) (n = 57)

43.26 (0–221.33)

(-) (n = 33)

42.88 (0–103.91)

0.723

Major organ involvement
(+) (n = 4)

44.3. (35.05–47.89)

(-) (n = 86)

43.26 (0–221.33)

0.314

(+): present; (-): absent
Mann–Whitney U test was used.

proved by the increased production of superoxide and
lysosomal enzymes. Alarmins are released as signaling
molecules after trauma, infection or injury [35]. When
the pattern recognition receptors of alarmins bind with
pathogen associated molecular pattern molecules, the
immune system is activated, proinflammatory cytokines
are released and inflammation is triggered. HMGB- 1 acts
as an alarmin in several tissues and activates the innate
immune system [36]. As a result, serum HMGB- 1 level
is considered to increase in BD as HMGB- 1 is a strong
stimulator of the innate immune system [34]. De Souza
et al. [24] found higher serum HMGB- 1 levels in the BD
group (n = 26) than in the HC group (n = 20), but they did
not show a relationship between BDCAF scores and serum
HMGB- 1 levels (p = 0.339). In our study, though, we
used both BSAS and BDCAF to evaluate disease activity
which are reliable, validated and frequently used indices,
and we found statistically significant but weakly positive
correlations between these scores and serum HMGB- 1
levels. The higher number of patients in our study might
have led to a significant relationship between activity
scores and serum HMGB- 1 level. In addition, de Souza et
al. used only BDCAF, but we used not only BDCAF but also
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BSAS, which is a newer activity measure of BD. To the best
of our knowledge, there is no study in the literature that
has evaluated the relationship between BSAS and HMGB1 level. As we found significantly positive correlations in
both indices, this may indicate our results being more
accurate and reliable.
In some studies, patients with BDCAF score ≥ 2 were
considered as “active” [24,25]. We also considered patients
with BDCAF ≥ 2 as active in our study and examined the
serum HMGB- 1 levels of active and inactive (BDCAF <
2) patients. We found significantly higher HMGB- 1 levels
in active patients. Serum levels of the cytokines involved
in neutrophils recruitment and activation such as CXCL8
and granulocyte-colony stimulating factor were shown
to be increased in active BD [16]. This result shows that
in active BD patients neutrophil activation is augmented
which can explain the elevated levels of serum HMGB- 1
level in active patients. De Souza et al. [24] also considered
patients with BDCAF score ≥ 2 as active, but found no
significant difference between the serum HMGB- 1 levels
of active (n = 13) and inactive (n = 13) patients. In the study
conducted with 42 BD patients and 22 HC in Korea [34], a
higher serum HMGB- 1 level in the BD group was found,
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Table 3. Comparison of serum HMGB- 1 levels in BD patients
with and without eye, vascular and MOI involvement since the
disease onset.
HMGB- 1 level
median (min - max)

p value

(+) (n = 28)

45.18 (5.46–58.29)

0.329

(-) (n = 62)

41.37 (0–221.33)

Eye involvement

Vascular involvement
(+) (n = 27)

45.56 (5.46–103.91)

(-) (n = 63)

42.5 (0–221.33)

0.552

Major organ involvement
(+) (n = 47)

44.79 (5.46–103.91)

(-) (n = 43)

37.15 (0–221.33)

0.212

Mann–Whitney U test was used.

and, even though, higher extracellular HMGB- 1 expression
in active patients (n = 25) compared to inactive patients (n
= 17) was shown, it was not statistically significant. This
study has defined active disease as follows: having at least
three of the following symptoms due to the worsening of
clinical findings during the study: oral ulcer or stomatitis,
genital ulcer, anterior iridocyclitis, posterior vasculitis or
panuveitis, cutaneous symptoms, or pathergy positivity [34].
In our study, the correlation of serum HMGB- 1 level with
other inflammatory markers such as ESR and CRP were
also examined, but no significant correlation was found.
Similarly, Ahn et al. [34] found no significant correlation
between serum HMGB- 1 level, ESR, CRP and leukocyte
count.
In our study, we also evaluated the association between
serum HMGB- 1 level and clinical findings of BD patients.
While mucocutaneous and joint involvements were
evaluated according to their presence in the last four
weeks, MOI (i.e. the presence of at least one involvement
of the eye, vascular, CNS, and GIS) was evaluated as both
by their presence in the last four weeks of recruitment and
since the onset of the disease as the number of patients with
current MOI was small in our study. However, we found no
association between serum HMGB- 1 level and the presence
of vascular, ocular and MOI as indicators of disease severity.
On the other hand, significantly higher serum HMGB- 1
levels were found only in patients with genital ulcer and
EN-like lesions. De Souza et al. [24] found no significant
correlation between serum HMGB- 1 levels and both
mucocutaneous and MOI (i.e., eye, neuro- and vasculoBehcet’s diseases). Ahn et al. [34] showed statistically
significant higher extracellular HMGB- 1 expression in

patients with intestinal involvement than in those without
intestinal involvement but could not found any association
between other clinical findings. RAGE, a transmembrane
protein belonging to the Ig superfamily, was the first receptor
described for HMGB- 1 [4]. RAGE is expressed at low
levels in normal tissues and vasculature but is upregulated
at sites where its ligands accumulate causing neutrophil
chemotaxis. Binding of RAGE by its ligands increases the
permeability of the vascular endothelium and enhances the
expression of adhesion molecules such as VCAM- 1 and
proinflammatory cytokines like procoagulant tissue factor
and or interleukin- 6 [37]. This is why it is thought that
HMGB- 1 plays a role in vascular involvement in BD [33].
Orogenital ulcerations and EN-like lesions are examples
of direct injury to vessel wall in BD [34]. In the study of
Demirkesen et al [38], a neutrophilic vasculitis was shown in
almost half of the nodular lesions of BD, and predominantly
neutrophil infiltration was statistically important parameter
proving the BD lesion. This may explain the high serum
HMGB- 1 levels in our patients with genital ulcers and ENlike lesions. In this study, the number of patients with MOI
in the last four weeks of recruitment was small, it might have
affected our results. Therefore, the correlation between MOI
and serum HMGB- 1 levels should be examined in further
studies conducted with larger number of patients.
This study has some limitations. First, this was a crosssectional study, which included only BD and HC. Association
of serum HMGB- 1 level with BD could be interpreted more
preciously if other inflammatory diseases were included as
control group. Even if we found a correlation between disease
activity indices and serum HMGB- 1 level, a prospective
study should be designed to evaluate the change in serum
HMGB- 1 level after appropriate disease control in active
patients. Secondly, as the number of patients with current
MOI was small, examining serum HMGB- 1 level with
larger number of active patients may be useful in clarifying
the role of HMGB- 1 in BD pathogenesis. In addition,
examining HMGB- 1 levels at the tissue level may also be
useful in explaining the correlation between HMGB- 1 and
BD. For this purpose, it can be suggested to study HMGB1 levels, in biopsy samples from active mucocutaneous
lesions and synovial fluid aspirates in patients with synovial
inflammation secondary to BD. Lastly, in order to investigate
the correlation of HMGB- 1 with other proinflammatory
cytokines involved in BD pathogenesis, these cytokine levels
in the serum can also be examined simultaneously.
5. Conclusion
In this study, higher serum HMGB- 1 level was found in
BD patients than in HC. Unlike other studies, this study
also showed that serum HMGB- 1 levels in BD patients
were positively correlated with BSAS and BDCAF scores.
These results suggest that HMGB- 1 may have a role in BD
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development and can be used to monitor disease activity.
These results should be supported by further studies that
include higher number of patients and patients with other
inflammatory diseases in order to clarify the association
between HMGB- 1 and BD.
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